SuperworthReplimune EPS REPL
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$3.16
- Latest quarter, Q1 FY27
- −$0.72
- Fiscal year 2026
- −$3.39
Replimune's earnings per share was −$3.16 over the twelve months to Jun 30, 2026.
In its latest quarter, Q1 FY27, it was −$0.72.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | −$3.39 | n/a |
| FY2025 | −$3.06 | n/a |
| FY2024 | −$3.25 | n/a |
| FY2023 | −$3.00 | n/a |
| FY2022 | −$2.26 | n/a |
| FY2021 | −$1.76 | n/a |
| FY2020 | −$1.52 | n/a |
| FY2019 | −$2.81 | n/a |
| FY2018 | −$3.89 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | −$0.72 | n/a | −$3.16 | |
| Q4 FY26 | −$0.77 | n/a | −$3.39 | |
| Q3 FY26 | −$0.77 | n/a | −$3.43 | |
| Q2 FY26 | −$0.90 | n/a | −$3.45 | |
| Q1 FY26 | −$0.95 | n/a | −$3.23 | |
| Q4 FY25 | −$0.81 | n/a | −$3.06 | |
| Q3 FY25 | −$0.79 | n/a | −$3.08 | |
| Q2 FY25 | −$0.68 | n/a | −$3.06 | |
| Q1 FY25 | −$0.78 | n/a | −$3.28 | |
| Q4 FY24 | −$0.83 | n/a | −$3.25 | |
| Q3 FY24 | −$0.77 | n/a | −$3.16 | |
| Q2 FY24 | −$0.90 | n/a | −$3.08 |
Against its peers
Companies in Biotechnology nearest Replimune's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| REPLReplimune | −$3.16 | |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| Peer median | $0.70 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Replimune
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.